The stock of Xenon Pharmaceuticals Inc (XENE) has seen a -9.55% decrease in the past week, with a -12.66% drop in the past month, and a -18.35% decrease in the past quarter. The volatility ratio for the week is 5.11%, and the volatility levels for the past 30 days are at 4.50% for XENE. The simple moving average for the last 20 days is -9.49% for XENE stock, with a simple moving average of -20.74% for the last 200 days.
Is It Worth Investing in Xenon Pharmaceuticals Inc (NASDAQ: XENE) Right Now?
Additionally, the 36-month beta value for XENE is 1.24. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for XENE is 74.20M and currently, short sellers hold a 4.91% ratio of that float. The average trading volume of XENE on April 03, 2025 was 460.25K shares.
XENE) stock’s latest price update
The stock price of Xenon Pharmaceuticals Inc (NASDAQ: XENE) has surged by 2.68 when compared to previous closing price of 30.64, but the company has seen a -9.55% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-12 that VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025.
Analysts’ Opinion of XENE
Many brokerage firms have already submitted their reports for XENE stocks, with Deutsche Bank repeating the rating for XENE by listing it as a “Buy.” The predicted price for XENE in the upcoming period, according to Deutsche Bank is $67 based on the research report published on February 11, 2025 of the current year 2025.
Raymond James, on the other hand, stated in their research note that they expect to see XENE reach a price target of $50. The rating they have provided for XENE stocks is “Outperform” according to the report published on October 10th, 2024.
H.C. Wainwright gave a rating of “Buy” to XENE, setting the target price at $53 in the report published on October 01st of the previous year.
XENE Trading at -15.66% from the 50-Day Moving Average
After a stumble in the market that brought XENE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.61% of loss for the given period.
Volatility was left at 4.50%, however, over the last 30 days, the volatility rate increased by 5.11%, as shares sank -15.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.29% lower at present.
During the last 5 trading sessions, XENE fell by -9.55%, which changed the moving average for the period of 200-days by -17.30% in comparison to the 20-day moving average, which settled at $34.76. In addition, Xenon Pharmaceuticals Inc saw -19.74% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XENE starting from MORTIMER IAN, who sale 22,468 shares at the price of $40.20 back on Jan 24 ’25. After this action, MORTIMER IAN now owns 31,302 shares of Xenon Pharmaceuticals Inc, valued at $903,214 using the latest closing price.
MORTIMER IAN, the PRESIDENT & CEO of Xenon Pharmaceuticals Inc, sale 16,315 shares at $40.50 during a trade that took place back on Jan 27 ’25, which means that MORTIMER IAN is holding 31,302 shares at $660,806 based on the most recent closing price.
Stock Fundamentals for XENE
The total capital return value is set at -0.37. Equity return is now at value -27.85, with -23.07 for asset returns.
Based on Xenon Pharmaceuticals Inc (XENE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -20.12.
Currently, EBITDA for the company is -279.3 million with net debt to EBITDA at 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.85.
Conclusion
In conclusion, Xenon Pharmaceuticals Inc (XENE) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
